Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol for Oxygen Reserve in ERCP
NCT06359834Completed
- Sponsor
- Yonsei University
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of remimazolam in hepatobiliary diseases (2 arms), sponsored by Yonsei University. Primary endpoint: Incidence of Oxygen Reserve Index (ORI) drop to 0.00 during sedation. Started Apr 2024; status: completed.
02
Drugs
remimazolam
03
Conditions
hepatobiliary diseases
Beyond the preview
Go deeper on NCT06359834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359834.